Pfizer Inc Stock Forecast:
The average analyst target price for Pfizer Inc. over the next 12 months is USD 49.17, with an average analyst rating of Hold. Stock Target Advisor‘s own analysis of Pfizer Inc is Bullish, based on 11 positive signals and 3 negative signals. Pfizer Inc’s current stock price is USD 41.79, having increased by +2.18% over the past week and +6.09% over the past month, but decreased by -22.51% over the last year.
Analysts Coverage Change:
Barclays maintains an “Equal-Weight” rating for Pfizer Inc.(PFE:NYE), and lowers the price target to $43 from $44 on the company’s stock.
Positive Fundamentals:
Investors like Pfizer Inc. stock because it has demonstrated superior total returns compared to its sector peers over the past five years. Additionally, it is currently underpriced compared to its earnings, book value, and cash flow, and has a low level of debt. The company has also shown positive cash flow and free cash flow in the most recent four quarters, and its management has delivered better return on equity, return on invested capital, and return on assets than its peers, placing it in the top quartile.
Negative Fundamentals:
Pfizer Inc. stock has poor risk adjusted returns, high volatility, and low dividend growth. The company has been delivering returns that are below median risk adjusted returns compared to its peers, and although it may outperform in terms of returns, these returns are unpredictable. Additionally, the total returns for the company are volatile and above median for its sector over the past five years, which may not be suitable for investors with low risk tolerance. Finally, Pfizer Inc. has shown below median dividend growth in the previous five years compared to its sector, which may make it less attractive to investors looking for steady dividend growth.
FA Score (Fundamental Analysis):
The fundamental analysis of Pfizer Inc. stock is “Bullish” with a FA score of 7.9 out of 10, where 0 is very bearish and 10 is very bullish.
